Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis

por Guo, Chang-Ying, Jiang, Si-Cong, Kuang, Yu-Kang, Hu, Hao
Publicado 2019

Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis

por Hu, Hao, Lin, Wei Qing, Zhu, Qian, Yang, Xiong Wen, Wang, Hai Dong, Kuang, Yu Kang
Publicado 2016

The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma

por Guo, Chang-Ying, Zhu, Qian, Tou, Fang-Fang, Wen, Xiao-Ming, Kuang, Yu-Kang, Hu, Hao
Publicado 2019

Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC

por Zhu, Qian, Hu, Hao, Jiang, Feng, Guo, Chang Ying, Yang, Xiong Wen, Liu, Xi, Kuang, Yu Kang
Publicado 2017